MD+DI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Case-Study Supports Seraph Blood Filter Helping COVID-19 Patients

TAGS: R&D
phonlamaiphoto -stock.adobe.com IMG_Aug112020at104616AM.jpg
The device was developed by ExThera Medical. In June, the Department of Defense announced it was funding a clinical trial of the device because it showed encouraging preliminary results in critically ill COVID-19 patients at a military hospital in the U.S. and 14 other hospitals in Europe.

A new peer-reviewed case-study shows ExThera Medical’s Seraph 100 extracorporeal blood filter could go a long way in helping COVID-19 patients.

The study was conducted by COL Stephen Olson, M.D., and colleagues at Walter Reed Army Medical Center determined that Martinez, CA-based ExThera Medical’s Seraph 100 extracorporeal blood filter may improve patient stability in COVID-19 cases requiring mechanical ventilation and vasopressor support.  

The study shows that the patients who were admitted into the ICU at Walter Reed Military Medical Center, experienced quantitative clinical improvement, and there were no device-related adverse events.

“The published study and several more recent cases indicate that Seraph has the potential to provide a greatly-needed solution for COVID-19 patients that other therapies and treatments are not able to address,” Robert Ward, President and CEO of ExThera Medical, said in a release. “Patients who are critically ill with SARS-CoV-2 virus have very limited options and we were very pleased to receive confirmation that the Seraph 100 treatment produced rapid and sustained improvement.”

ExThera said the treatments were performed in spring of 2020. The treatments not only led the way to Emergency Use Authorization from FDA but also a multi-center trial of COVID-19 treatment using the Seraph funded by the U.S. Department of Defense (DOD) set to begin next month.

The DOD selected the Seraph as one of its main interventions in a prospective observational study for COVID-19 patients.

In a release about DoD’s funding,  it was stated that it appears as if the Seraph 100 helps improve patient outcomes by providing additional time for supportive care while reducing the sources of inflammation and possibly preventing further damage by reducing SARS-CoV-2 virus/RNA in the bloodstream.

Recently, MD+DI included Exthera’s Seraph as one of several devices with the potential to either treat or manage COVID-19 symptoms.

Hide comments
account-default-image

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish